Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Scott Butsch

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
BMC Family Practice|June 25, 2021
Benchmarking of provider competencies and current training for prevention and management of obesity among family medicine residency programs: a cross-sectional surveyManuela Orjuela-Grimm, W Scott Butsch, Silvia Bhatt-Carreño, et al.
Teaching and Learning in Medicine|December 30, 2016
Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested?Robert F Kushner, W Scott Butsch, Scott Kahan, et al.
JAMA Network Open|September 13, 2024
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical PracticeHamlet Gasoyan, Elizabeth R Pfoh, Rebecca Schulte, et al.
International Journal of Laboratory Hematology|October 20, 2021
A comprehensive analysis of cytopenias and bone marrow morphology in patients with a history of bariatric and metabolic surgeryFrido K Bruehl, David S Bosler, W Scott Butsch, et al.
Obesity Science & Practice|August 7, 2023
Health state utilities associated with hyperphagia: Data for use in cost-utility modelsTimothy A Howell, Louis S Matza, Usha G Mallya, et al.
International Journal of Obesity (2005)|September 28, 2023
Obesity preclinical elective: a qualitative thematic analysis of student feedbackAmber Olson, Katherine Lyons, Rosanna Watowicz, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|September 19, 2024
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesityJeffrey I Mechanick, W Scott Butsch, Sandra M Christensen, et al.
Journal of Clinical & Translational Endocrinology|October 10, 2024
Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort studyArunkumar Krishnan, Carolin V Schneider, Hendrik-Tobias Arkenau, et al.
Obesity (Silver Spring, Md.)|June 10, 2025
Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation statusHamlet Gasoyan, W Scott Butsch, Rebecca Schulte, et al.
Obesity (Silver Spring, Md.)|October 3, 2025
Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical PracticeHamlet Gasoyan, W Scott Butsch, Nicholas J Casacchia, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
BMC Family Practice|June 25, 2021
Benchmarking of provider competencies and current training for prevention and management of obesity among family medicine residency programs: a cross-sectional surveyManuela Orjuela-Grimm, W Scott Butsch, Silvia Bhatt-Carreño, et al.
Teaching and Learning in Medicine|December 30, 2016
Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested?Robert F Kushner, W Scott Butsch, Scott Kahan, et al.
JAMA Network Open|September 13, 2024
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical PracticeHamlet Gasoyan, Elizabeth R Pfoh, Rebecca Schulte, et al.
International Journal of Laboratory Hematology|October 20, 2021
A comprehensive analysis of cytopenias and bone marrow morphology in patients with a history of bariatric and metabolic surgeryFrido K Bruehl, David S Bosler, W Scott Butsch, et al.
Obesity Science & Practice|August 7, 2023
Health state utilities associated with hyperphagia: Data for use in cost-utility modelsTimothy A Howell, Louis S Matza, Usha G Mallya, et al.
International Journal of Obesity (2005)|September 28, 2023
Obesity preclinical elective: a qualitative thematic analysis of student feedbackAmber Olson, Katherine Lyons, Rosanna Watowicz, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|September 19, 2024
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesityJeffrey I Mechanick, W Scott Butsch, Sandra M Christensen, et al.
Journal of Clinical & Translational Endocrinology|October 10, 2024
Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort studyArunkumar Krishnan, Carolin V Schneider, Hendrik-Tobias Arkenau, et al.
Obesity (Silver Spring, Md.)|June 10, 2025
Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation statusHamlet Gasoyan, W Scott Butsch, Rebecca Schulte, et al.
Obesity (Silver Spring, Md.)|October 3, 2025
Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical PracticeHamlet Gasoyan, W Scott Butsch, Nicholas J Casacchia, et al.
Pageof 5